➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Moodys
Medtronic
Boehringer Ingelheim
Johnson and Johnson

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,192,571

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,192,571 protect, and when does it expire?

Patent 9,192,571 protects ACUVAIL and is included in one NDA.

This patent has fifty patent family members in twenty-four countries.

Summary for Patent: 9,192,571
Title:Ketorolac tromethamine compositions for treating or preventing ocular pain
Abstract: The present invention provides an aqueous ophthalmic solution with an effective amount of ketorolac and carboxymethyl cellulose in an aqueous solution which provides increased visual acuity and wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.
Inventor(s): Farnes; Eldon Q. (Laguna Beach, CA), Attar; Mayssa (Placentia, CA), Schiffman; Rhett M. (Laguna Beach, CA), Chang; Chin-Ming (Tustin, CA), Graham; Richard S. (Irvine, CA), Welty; Devin F. (Foothill Ranch, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:12/552,057
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound;

Drugs Protected by US Patent 9,192,571

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan ACUVAIL ketorolac tromethamine SOLUTION/DROPS;OPHTHALMIC 022427-001 Jul 22, 2009 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,192,571

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Australia2009202969Jul 23, 2009

International Family Members for US Patent 9,192,571

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 538775   Start Trial
Australia 2009202969   Start Trial
Australia 2009222016   Start Trial
Australia 2010289618   Start Trial
Australia 2011237646   Start Trial
Brazil PI0909100   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Boehringer Ingelheim
Merck
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.